The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...
Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...
Adam Jacobson, MD, and colleagues retrospectively investigated how glaucoma affects the eyes of pediatric patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results